Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
Summary: Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guide...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 June 2017
|
| In: |
The lancet. Respiratory medicine
Year: 2017, Volume: 5, Issue: 7, Pages: 591-598 |
| ISSN: | 2213-2619 |
| DOI: | 10.1016/S2213-2600(17)30219-9 |
| Online Access: | Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S2213260017302199 Verlag, Volltext: http://dx.doi.org/10.1016/S2213-2600(17)30219-9 
|
| Author Notes: | Kerri A Johannson, Irina Strâmbu, Claudia Ravaglia, Jan C Grutters, Claudia Valenzuela, Nesrin Mogulkoc, Fabrizio Luppi, Luca Richeldi, Athol U Wells, Carlo Vancheri, Michael Kreuter, Carlo Albera, Katerina M. Antoniou, Goksel Altinisik, Elisabeth Bendstrup, Benjamin Bondue, Raphael Borie, Kevin K. Brown, Philippe Camus, Diego Castillo, Harold R. Collard, Vincent Cottin, Nunzio Crimi, Giovanni Ferrara, Aryeh Fischer, Jack Gauldie, Thomas Geiser, Andreas Guenther, Nathan Hambly, David M. Hansell, Sergio Harari, Mark G. Jones, Michael Keane, Brett Ley, Toby M. Maher, Maria Molina-Molina, Stefano Palmucci, Venerino Poletti, Antje Prasse, Paola Rottoli, Paolo Spagnolo, Martina Sterclova, Sebastiano Torrisi, Eliza Tsitoura, Martina Vasakova, Simon L. Walsh, Marlies S. Wijsenbeek, Wim A. Wuyts |
| Summary: | Summary: Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF. |
|---|---|
| Item Description: | Gesehen am 13.10.2018 |
| Physical Description: | Online Resource |
| ISSN: | 2213-2619 |
| DOI: | 10.1016/S2213-2600(17)30219-9 |